Cellular and molecular biology of aging endothelial cells

Journal of Molecular and Cellular Cardiology

Volumn 89, Issue , 2015, Pages 122-135

  Donato, Anthony J ^a,b   Morgan, R Garrett ^c   Walker, Ashley E ^a   Lesniewski, Lisa A ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Aging; Endothelium; Genomic instability; Inflammation; Oxidative stress; Senescence

Indexed keywords

ADENYLATE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; NITRIC OXIDE; PROTEIN P53; SIRTUIN 1; TRANSCRIPTION FACTOR FOXO;

BIOAVAILABILITY; CARDIOVASCULAR DISEASE; CELL AGING; CELL ENERGY; CYTOLOGY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENOMIC INSTABILITY; HUMAN; INFLAMMATION; LONGEVITY; MOLECULAR BIOLOGY; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; VASCULAR ENDOTHELIUM; ANIMAL; ENERGY METABOLISM; PATHOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; CELL AGING; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENERGY METABOLISM; GENOMIC INSTABILITY; HUMANS;

EID: 84934906739     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.01.021     Document Type: Review

References (287)

1. Health United States With special feature on death and dying 2010, [Hyattsville (MD)2011].
2. Lakatta E., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease. Circulation 2003, 107:139-146.
3. Widlansky M.E., Gokce N., Keaney J.F., Vita J.A. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003, 42:1149-1160.
4. Franklin S.S., Khan S.A., Wong N.D., Larson M.G., Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 1999, 100:354-360.
5. Franklin S.S., Larson M.G., Khan S.A., Wong N.D., Leip E.P., Kannel W.B., et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001, 103:1245-1249.
6. Seals D.R., Jablonski K.L., Donato A.J. Aging and vascular endothelial function in humans. Clin Sci (Lond) 2011, 120:357-375.
7. Lakatta E.G., Wang M., Najjar S.S. Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. Med Clin North Am 2009, 93:583-604. [Table of Contents].
8. Nagai Y., Metter E.J., Earley C.J., Kemper M.K., Becker L.C., Lakatta E.G., et al. Increased carotid artery intimal-medial thickness in asymptomatic older subjects with exercise-induced myocardial ischemia. Circulation 1998, 98:1504-1509.
9. Celermajer D.S., Sorensen K.E., Spiegelhalter D.J., Georgakopoulos D., Robinson J., Deanfield J.E. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 1994, 24:471-476.
10. Vaitkevicius P.V., Fleg J.L., Engel J.H., O'Connor F.C., Wright J.G., Lakatta L.E., et al. Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation 1993, 88:1456-1462.
11. Asai K., Kudej R.K., Shen Y.T., Yang G.P., Takagi G., Kudej A.B., et al. Peripheral vascular endothelial dysfunction and apoptosis in old monkeys. Arterioscler Thromb Vasc Biol 2000, 20:1493-1499.
12. Li Z., Froehlich J., Galis Z.S., Lakatta E.G. Increased expression of matrix metalloproteinase-2 in the thickened intima of aged rats. Hypertension 1999, 33:116-123.
13. Haudenschild C.C., Prescott M.F., Chobanian A.V. Aortic endothelial and subendothelial cells in experimental hypertension and aging. Hypertension 1981, 3:I148-I153.
14. Franklin S.S., Wt Gustin, Wong N.D., Larson M.G., Weber M.A., Kannel W.B., et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997, 96:308-315.
15. R B, I F Vascular endothelium and blood flow. Handb Exp Pharmacol 2006, 176(43).
16. Pober J.S., Min W., Bradley J.R. Mechanisms of endothelial dysfunction, injury, and death. Annu Rev Pathol 2009, 4:71-95.
17. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease. Circulation 2003, 107:139-146.
18. Mitchell G.F., Parise H., Vita J.A., Larson M.G., Warner E., Keaney J.F., et al. Local shear stress and brachial artery flow-mediated dilation: the Framingham Heart Study. Hypertension 2004, 44:134-139.
19. Donato A.J., Gano L.B., Eskurza I., Silver A.E., Gates P.E., Jablonski K., et al. Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol 2009, 297:H425-H432.
20. DeSouza C., Shapiro L., Clevenger C., Dinenno F., Monahan K., Tanaka H., et al. Regular aerobic exercise prevents and restores age-related declines in endothelium-dependent vasodilation in healthy men. Circulation 2000, 102:1351-1357.
21. Eskurza I., Monahan K.D., Robinson J.A., Seals D.R. Effect of acute and chronic ascorbic acid on flow-mediated dilatation with sedentary and physically active human ageing. J Physiol 2004, 556:315-324.
22. Donato A.J., Eskurza I., Silver A.E., Levy A.S., Pierce G.L., Gates P.E., et al. Direct evidence of endothelial oxidative stress with aging in humans: relation to impaired endothelium-dependent dilation and upregulation of nuclear factor-kappaB. Circ Res 2007, 100:1659-1666.
23. Gerhard M., Roddy M., Creager S., Creager M. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension 1996, 27:849-853.
24. Taddei S., Galetta F., Virdis A., Ghiadoni L., Salvetti G., Franzoni F., et al. Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes. Circulation 2000, 101:2896-2901.
25. Smith D.T., Hoetzer G.L., Greiner J.J., Stauffer B.L., DeSouza C.A. Effects of ageing and regular aerobic exercise on endothelial fibrinolytic capacity in humans. J Physiol 2003, 546:289-298.
26. Blau C.W., Cowley T.R., O'Sullivan J., Grehan B., Browne T.C., Kelly L., et al. The age-related deficit in LTP is associated with changes in perfusion and blood-brain barrier permeability. Neurobiol Aging 2012, 33(1005):e23-e35.
27. Croley A.N., Zwetsloot K.A., Westerkamp L.M., Ryan N.A., Pendergast A.M., Hickner R.C., et al. Lower capillarization, VEGF protein, and VEGF mRNA response to acute exercise in the vastus lateralis muscle of aged vs. young women. J Appl Physiol 2005, 99:1872-1879. [1985].
28. Ryan N.A., Zwetsloot K.A., Westerkamp L.M., Hickner R.C., Pofahl W.E., Gavin T.P. Lower skeletal muscle capillarization and VEGF expression in aged vs. young men. J Appl Physiol 2006, 100:178-185. [1985].
29. Lesniewski L.A., Connell M.L., Durrant J.R., Folian B.J., Anderson M.C., Donato A.J., et al. B6D2F1 Mice are a suitable model of oxidative stress-mediated impaired endothelium-dependent dilation with aging. J Gerontol A Biol Sci Med Sci 2009, 64:9-20.
30. Yamamoto K., Takeshita K., Shimokawa T., Yi H., Isobe K., Loskutoff D.J., et al. Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proc Natl Acad Sci U S A 2002, 99:890-895.
31. Pelegri C., Canudas A.M., del Valle J., Casadesus G., Smith M.A., Camins A., et al. Increased permeability of blood-brain barrier on the hippocampus of a murine model of senescence. Mech Ageing Dev 2007, 128:522-528.
32. Zhuo Y., Li S.H., Chen M.S., Wu J., Kinkaid H.Y., Fazel S., et al. Aging impairs the angiogenic response to ischemic injury and the activity of implanted cells: combined consequences for cell therapy in older recipients. J Thorac Cardiovasc Surg 2010, 139:1286-1294. [94 e1-2].
33. Taddei S., Virdis A., Mattei P., Ghiadoni L., Gennari A., Fasolo C.B., et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995, 91:1981-1987.
34. Walker A.E., Eskurza I., Pierce G.L., Gates P.E., Seals D.R. Modulation of vascular endothelial function by low-density lipoprotein cholesterol with aging: influence of habitual exercise. Am J Hypertens 2009, 22:250-256.
35. DeVan A.E., Eskurza I., Pierce G.L., Walker A.E., Jablonski K.L., Kaplon R.E., et al. Regular aerobic exercise protects against impaired fasting plasma glucose-associated vascular endothelial dysfunction with aging. Clin Sci (Lond) 2013, 124:325-331.
36. Jablonski K.L., Gates P.E., Pierce G.L., Seals D.R. Low dietary sodium intake is associated with enhanced vascular endothelial function in middle-aged and older adults with elevated systolic blood pressure. Ther Adv Cardiovasc Dis 2009, 3:347-356.
37. Walker A.E., Seibert S.M., Donato A.J., Pierce G.L., Seals D.R. Vascular endothelial function is related to white blood cell count and myeloperoxidase among healthy middle-aged and older adults. Hypertension 2010, 55:363-369.
38. Kaplon R.E., Walker A.E., Seals D.R. Plasma norepinephrine is an independent predictor of vascular endothelial function with aging in healthy women. J Appl Physiol 2011, 111:1416-1421. [1985].
39. Basu R., Dalla Man C., Campioni M., Basu A., Klee G., Toffolo G., et al. Effects of age and sex on postprandial glucose metabolism: differences in glucose turnover, insulin secretion, insulin action, and hepatic insulin extraction. Diabetes 2006, 55:2001-2014.
40. Issa J.S., Diament J. Forti N. Arq Bras Cardiol 2005, 85:15-19.
41. Marchesi S., Lupattelli G., Schillaci G., Pirro M., Siepi D., Roscini A.R., et al. Impaired flow-mediated vasoactivity during post-prandial phase in young healthy men. Atherosclerosis 2000, 153:397-402.
42. Rudolph T.K., Ruempler K., Schwedhelm E., Tan-Andresen J., Riederer U., Boger R.H., et al. Acute effects of various fast-food meals on vascular function and cardiovascular disease risk markers: the Hamburg Burger Trial. Am J Clin Nutr 2007, 86:334-340.
43. Wu Y., Song P., Xu J., Zhang M., Zou M.H. Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J Biol Chem 2007, 282:9777-9788.
44. Chakrabarti S., Davidge S.T. High glucose-induced oxidative stress alters estrogen effects on ERalpha and ERbeta in human endothelial cells: reversal by AMPK activator. J Steroid Biochem Mol Biol 2009, 117:99-106.
45. Mortuza R., Chen S., Feng B., Sen S., Chakrabarti S. High glucose induced alteration of SIRTs in endothelial cells causes rapid aging in a p300 and FOXO regulated pathway. PLoS One 2013, 8:e54514.
46. Alp N.J., Channon K.M. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 2004, 24:413-420.
47. Ganz P., Vita J.A. Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation 2003, 108:2049-2053.
48. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993, 329:2002-2012.
49. Luscher T.F., Barton M. Biology of the endothelium. Clin Cardiol 1997, 20(II):3-10.
50. Cernadas M.R., Sanchez de Miguel L., Garcia-Duran M., Gonzalez-Fernandez F., Millas I., Monton M., et al. Expression of constitutive and inducible nitric oxide synthases in the vascular wall of young and aging rats. Circ Res 1998, 83:279-286.
51. Chou T.C., Yen M.H., Li C.Y., Ding Y.A. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension 1998, 31:643-648.
52. Csiszar A., Labinskyy N., Smith K., Rivera A., Orosz Z., Ungvari Z. Vasculoprotective effects of anti-tumor necrosis factor-alpha treatment in aging. Am J Pathol 2007, 170:388-398.
53. van der Loo B., Labugger R., Skepper J.N., Bachschmid M., Kilo J., Powell J.M., et al. Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med 2000, 192:1731-1744.
54. Spier S.A., Delp M.D., Meininger C.J., Donato A.J., Ramsey M.W., Muller-Delp J.M. Effects of ageing and exercise training on endothelium-dependent vasodilatation and structure of rat skeletal muscle arterioles. J Physiol 2004, 556:947-958.
55. Durrant J.R., Seals D.R., Connell M.L., Russell M.J., Lawson B.R., Folian B.J., et al. Voluntary wheel running restores endothelial function in conduit arteries of old mice: direct evidence for reduced oxidative stress, increased superoxide dismutase activity and down-regulation of NADPH oxidase. J Physiol 2009, 587:3271-3285.
56. Spier S.A., Delp M.D., Stallone J.N., Dominguez J.M., Muller-Delp J.M. Exercise training enhances flow-induced vasodilation in skeletal muscle resistance arteries of aged rats: role of PGI2 and nitric oxide. Am J Physiol Heart Circ Physiol 2007, 292:H3119-H3127.
57. Nicholson W.T., Vaa B., Hesse C., Eisenach J.H., Joyner M.J. Aging is associated with reduced prostacyclin-mediated dilation in the human forearm. Hypertension 2009, 53:973-978.
58. Novella S., Dantas A.P., Segarra G., Novensa L., Heras M., Hermenegildo C., et al. Aging enhances contraction to thromboxane A2 in aorta from female senescence-accelerated mice. Age (Dordr) 2013, 35:117-128.
59. Cardillo C., Kilcoyne C.M., Cannon R.O., Panza J.A. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 2000, 35:1237-1241.
60. Tang E.H., Vanhoutte P.M. Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension. Physiol Genomics 2008, 32:409-418.
61. Goettsch W., Lattmann T., Amann K., Szibor M., Morawietz H., Munter K., et al. Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo: implications for atherosclerosis. Biochem Biophys Res Commun 2001, 280:908-913.
62. Westby C.M., Weil B.R., Greiner J.J., Stauffer B.L., DeSouza C.A. Endothelin-1 vasoconstriction and the age-related decline in endothelium-dependent vasodilatation in men. Clin Sci (Lond) 2011, 120:485-491.
63. JI L.L., LEEUWENBURGH C., LEICHTWEIS S., GORE M., FIEBIG R., HOLLANDER J., et al. Oxidative stress and aging: role of exercise and its influences on antioxidant systems. Ann N Y Acad Sci 1998, 854:102-117.
64. Moreau K.L., Donato A.J., Tanaka H., Jones P.P., Gates P.E., Seals D.R. Basal leg blood flow in healthy women is related to age and hormone replacement therapy status. J Physiol 2003, 547:309-316.
65. Franzoni F., Ghiadoni L., Galetta F., Plantinga Y., Lubrano V., Huang Y., et al. Physical activity, plasma antioxidant capacity, and endothelium-dependent vasodilation in young and older men. Am J Hypertens 2005, 18:510.
66. Taddei S., Virdis A., Ghiadoni L., Salvetti G., Bernini G., Magagna A., et al. Age-related reduction of NO availability and oxidative stress in humans. Hypertension 2001, 38:274-279.
67. Cohen R.A., Plane F., Najibi S., Huk I., Malinski T., Garland C.J. Nitric oxide is the mediator of both endothelium-dependent relaxation and hyperpolarization of the rabbit carotid artery. Proc Natl Acad Sci U S A 1997, 94:4193-4198.
68. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43:109-142.
69. Persson M.G., Gustafsson L.E., Wiklund N.P., Hedqvist P., Moncada S. Endogenous nitric oxide as a modulator of rabbit skeletal muscle microcirculation in vivo. Br J Pharmacol 1990, 100:463-466.
70. Griendling K.K., Sorescu D., Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000, 86:494-501.
71. Harrison D.G. Endothelial function and oxidant stress. Clin Cardiol 1997, 20(II):11-17.
72. Price D.T., Vita J.A., Keaney J.F. Redox control of vascular nitric oxide bioavailability. Antioxid Redox Signal 2000, 2:919-935.
73. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000, 87:840-844.
74. Mervaala E.M., Cheng Z.J., Tikkanen I., Lapatto R., Nurminen K., Vapaatalo H., et al. Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension 2001, 37:414-418.
75. Hamilton C.A., Brosnan M.J., McIntyre M., Graham D., Dominiczak A.F. Superoxide excess in hypertension and aging: a common cause of endothelial dysfunction. Hypertension 2001, 37:529-534.
76. Dikalov S.I., Ungvari Z. Role of mitochondrial oxidative stress in hypertension. Am J Physiol Heart Circ Physiol 2013, 305:H1417-H1427.
77. Quijano C., Castro L., Peluffo G., Valez V., Radi R. Enhanced mitochondrial superoxide in hyperglycemic endothelial cells: direct measurements and formation of hydrogen peroxide and peroxynitrite. Am J Physiol Heart Circ Physiol 2007, 293:H3404-H3414.
78. Baker C.S., Hall R.J., Evans T.J., Pomerance A., Maclouf J., Creminon C., et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 1999, 19:646-655.
79. Myatt L., Rosenfield R.B., Eis A.L., Brockman D.E., Greer I., Lyall F. Nitrotyrosine residues in placenta. Evidence of peroxynitrite formation and action. Hypertension 1996, 28:488-493.
80. Miller S.J., Watson W.C., Kerr K.A., Labarrere C.A., Chen N.X., Deeg M.A., et al. Development of progressive aortic vasculopathy in a rat model of aging. Am J Physiol Heart Circ Physiol 2007, 293:H2634-H2643.
81. Oelze M., Kroller-Schon S., Steven S., Lubos E., Doppler C., Hausding M., et al. Glutathione peroxidase-1 deficiency potentiates dysregulatory modifications of endothelial nitric oxide synthase and vascular dysfunction in aging. Hypertension 2014, 63:390-396.
82. Gong X., Ma Y., Ruan Y., Fu G., Wu S. Long-term atorvastatin improves age-related endothelial dysfunction by ameliorating oxidative stress and normalizing eNOS/iNOS imbalance in rat aorta. Exp Gerontol 2014, 52:9-17.
83. Ungvari Z., Bailey-Downs L., Gautam T., Sosnowska D., Wang M., Monticone R.E., et al. Age-associated vascular oxidative stress, Nrf2 dysfunction, and NF-{kappa}B activation in the nonhuman primate Macaca mulatta. J Gerontol A Biol Sci Med Sci 2011, 66:866-875.
84. Uddin M., Yang H., Shi M., Polley-Mandal M., Guo Z. Elevation of oxidative stress in the aorta of genetically hypertensive mice. Mech Ageing Dev 2003, 124:811-817.
85. Tatchum-Talom R., Martin D.S. Tempol improves vascular function in the mesenteric vascular bed of senescent rats. Can J Physiol Pharmacol 2004, 82:200-207.
86. Trott D.W., Seawright J.W., Luttrell M.J., Woodman C.R. NAD(P)H oxidase-derived reactive oxygen species contribute to age-related impairments of endothelium-dependent dilation in rat soleus feed arteries. J Appl Physiol 2011, 110:1171-1180. [1985].
87. Wever R.M., van Dam T., van Rijn H.J., de Groot F., Rabelink T.J. Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun 1997, 237:340-344.
88. Eskurza I., Myerburgh L.A., Kahn Z.D., Seals D.R. Tetrahydrobiopterin augments endothelium-dependent dilatation in sedentary but not in habitually exercising older adults. J Physiol 2005, 568:1057-1065.
89. Sindler A.L., Delp M.D., Reyes R., Wu G., Muller-Delp J.M. Effects of ageing and exercise training on eNOS uncoupling in skeletal muscle resistance arterioles. J Physiol 2009, 587:3885-3897.
90. Eskurza I., Kahn Z., Seals D. Xanthine oxidase does not contribute to impaired peripheral artery conduit artery endothelium-dependent dilatation with aging. J Physiol 2006, 571:661-668.
91. Donato A.J., Black A.D., Jablonski K.L., Gano L.B., Seals D.R. Aging is associated with greater nuclear NFkappaB, reduced IkappaBalpha, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans. Aging Cell 2008, 7:805-812.
92. Donato A.J., Eskurza I., Jablonski K.L., Gano L.B., Pierce G.L., Seals D.R. Cytochrome P-450 2C9 signaling does not contribute to age-associated vascular endothelial dysfunction in humans. J Appl Physiol 2008, 105:1359-1363.
93. Ungvari Z.I., Labinskyy N., Gupte S.A., Chander P.N., Edwards J.G., Csiszar A. Dysregulation of mitochondrial biogenesis in vascular endothelial and smooth muscle cells of aged rats. Am J Physiol Heart Circ Physiol 2008, 294:H2121-H2128.
94. Gioscia-Ryan R.A., LaRocca T.J., Sindler A.L., Zigler M.C., Murphy M.P., Seals D.R. Mitochondria-targeted antioxidant (MitoQ) ameliorates age-related arterial endothelial dysfunction in mice. J Physiol 2014, 592:2549-2561.
95. Francia P., delli Gatti C., Bachschmid M., Martin-Padura I., Savoia C., Migliaccio E., et al. Deletion of p66shc gene protects against age-related endothelial dysfunction. Circulation 2004, 110:2889-2895.
96. Brown K.A., Didion S.P., Andresen J.J., Faraci F.M. Effect of aging, MnSOD deficiency, and genetic background on endothelial function: evidence for MnSOD haploinsufficiency. Arterioscler Thromb Vasc Biol 2007, 27:1941-1946.
97. Dikalov S.I., Dikalova A.E., Bikineyeva A.T., Schmidt H.H., Harrison D.G., Griendling K.K. Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic Biol Med 2008, 45:1340-1351.
98. Woodman C.R., Price E.M., Laughlin M.H. Aging induces muscle-specific impairment of endothelium-dependent dilation in skeletal muscle feed arteries. J Appl Physiol 2002, 93:1685-1690.
99. Tian L., Cai Q., Wei H. Alterations of antioxidant enzymes and oxidative damage to macromolecules in different organs of rats during aging. Free Radic Biol Med 1998, 24:1477-1484.
100. Demaree S.R., Lawler J.M., Linehan J., Delp M.D. Ageing alters aortic antioxidant enzyme activities in Fischer-344 rats. Acta Physiol Scand 1999, 166:203-208.
101. Brandes R.P., Fleming I., Busse R. Endothelial aging. Cardiovasc Res 2005, 66:286-294.
102. Sindler A.L., Reyes R., Chen B., Ghosh P., Gurovich A.N., Kang L.S., et al. Age and exercise training alter signaling through reactive oxygen species in the endothelium of skeletal muscle arterioles. J Appl Physiol 2013, 114:681-693. [1985].
103. MacMillan-Crow L.A., Crow J.P., Thompson J.A. Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry 1998, 37:1613-1622.
104. Donato A.J., Walker A.E., Magerko K.A., Bramwell R.C., Black A.D., Henson G.D., et al. Life-long caloric restriction reduces oxidative stress and preserves nitric oxide bioavailability and function in arteries of old mice. Aging Cell 2013, 12:772-783.
105. Walker A.E., Henson G.D., Reihl K.D., Nielson E.I., Morgan R.G., Lesniewski L.A., et al. Beneficial effects of lifelong caloric restriction on endothelial function are greater in conduit arteries compared to cerebral resistance arteries. Age (Dordr) 2014, 36:559-569.
106. Donato A.J., Uberoi A., Bailey D.M., Wray D.W., Richardson R.S. Exercise-induced brachial artery vasodilation: effects of antioxidants and exercise training in elderly men. Am J Physiol Heart Circ Physiol 2010, 298:H671-H678.
107. Miura H., Bosnjak J.J., Ning G., Saito T., Miura M., Gutterman D.D. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ Res 2003, 92:e31-e40.
108. Kang L.S., Reyes R.A., Muller-Delp J.M. Aging impairs flow-induced dilation in coronary arterioles: role of NO and H(2)O(2). Am J Physiol Heart Circ Physiol 2009, 297:H1087-H1095.
109. Krabbe K., Pedersen M., Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol 2004, 39:687-699.
110. Vgontzas A.N., Zoumakis M., Bixler E.O., Lin H.M., Prolo P., Vela-Bueno A., et al. Impaired nighttime sleep in healthy old versus young adults is associated with elevated plasma interleukin-6 and cortisol levels: physiologic and therapeutic implications. J Clin Endocrinol Metab 2003, 88:2087-2095.
111. Belmin J., Bernard C., Corman B., Merval R., Esposito B., Tedgui A. Increased production of tumor necrosis factor and interleukin-6 by arterial wall of aged rats. Am J Physiol 1995, 268:H2288-H2293.
112. Lesniewski L.A., Durrant J.R., Connell M.L., Henson G.D., Black A.D., Donato A.J., et al. Aerobic exercise reverses arterial inflammation with aging in mice. Am J Physiol Heart Circ Physiol 2011, 301:H1025-H1032.
113. Lesniewski L.A., Durrant J.R., Connell M.L., Folian B.J., Donato A.J., Seals D.R. Salicylate treatment improves age-associated vascular endothelial dysfunction: potential role of nuclear factor kappaB and forkhead Box O phosphorylation. J Gerontol A Biol Sci Med Sci 2011, 66:409-418.
114. Wang M., Zhang J., Jiang L.Q., Spinetti G., Pintus G., Monticone R., et al. Proinflammatory profile within the grossly normal aged human aortic wall. Hypertension 2007, 50:219-227.
115. Read M.A., Whitley M.Z., Williams A.J., Collins T. NF-kappa B and I kappa B alpha: an inducible regulatory system in endothelial activation. J Exp Med 1994, 179:503-512.
116. Karin M., Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol 2000, 12:85-98.
117. van den Berg R., Haenen G.R., van den Berg H., Bast A. Transcription factor NF-kappaB as a potential biomarker for oxidative stress. Br J Nutr 2001, 86(Suppl. 1):S121-S127.
118. Schreck R., Albermann K., Baeuerle P.A. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun 1992, 17:221-237.
119. Schreck R., Rieber P., Baeuerle P.A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 1991, 10:2247-2258.
120. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-{kappa}B activity. Annu Rev Immunol 2000, 18:621-663.
121. Walker A.E., Kaplon R.E., Pierce G.L., Nowlan M.J., Seals D.R. Prevention of age-related endothelial dysfunction by habitual aerobic exercise in healthy humans: possible role of nuclear factor kappaB. Clin Sci (Lond) 2014, 127:645-654.
122. Pierce G.L., Lesniewski L.A., Lawson B.R., Beske S.D., Seals D.R. Nuclear factor-[kappa]B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans. Circulation 2009, 119:1284-1292.
123. Csiszar A., Smith K., Labinskyy N., Orosz Z., Rivera A., Ungvari Z. Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kappaB inhibition. Am J Physiol Heart Circ Physiol 2006, 291:H1694-H1699.
124. Xiao J., Song J., Hodara V., Ford A., Wang X.L., Shi Q., et al. Protective effects of resveratrol on TNF-alpha-induced endothelial cytotoxicity in baboon femoral arterial endothelial cells. J Diabet Res 2013, 2013:185172.
125. Donato A.J., Henson G.D., Morgan R.G., Enz R.A., Walker A.E., Lesniewski L.A. TNF-alpha impairs endothelial function in adipose tissue resistance arteries of mice with diet-induced obesity. Am J Physiol Heart Circ Physiol 2012, 303:H672-H679.
126. Manea A., Manea S.A., Gafencu A.V., Raicu M. Regulation of NADPH oxidase subunit p22(phox) by NF-kB in human aortic smooth muscle cells. Arch Physiol Biochem 2007, 113:163-172.
127. Kuwano Y., Kawahara T., Yamamoto H., Teshima-Kondo S., Tominaga K., Masuda K., et al. Interferon-gamma activates transcription of NADPH oxidase 1 gene and upregulates production of superoxide anion by human large intestinal epithelial cells. Am J Physiol Cell Physiol 2006, 290:C433-C443.
128. Anrather J., Racchumi G., Iadecola C. NF-kappaB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. J Biol Chem 2006, 281:5657-5667.
129. Hasegawa Y., Saito T., Ogihara T., Ishigaki Y., Yamada T., Imai J., et al. Blockade of the nuclear factor-kappaB pathway in the endothelium prevents insulin resistance and prolongs life spans. Circulation 2012, 125:1122-1133.
130. Schraufstatter I.U., Chung J., Burger M. IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways. Am J Physiol Lung Cell Mol Physiol 2001, 280:L1094-L1103.
131. Mannell H.K., Pircher J., Chaudhry D.I., Alig S.K., Koch E.G., Mettler R., et al. ARNO regulates VEGF-dependent tissue responses by stabilizing endothelial VEGFR-2 surface expression. Cardiovasc Res 2012, 93:111-119.
132. Zhu W., London N.R., Gibson C.C., Davis C.T., Tong Z., Sorensen L.K., et al. Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability. Nature 2012, 492:252-255.
133. van Wetering S., van den Berk N., van Buul J.D., Mul F.P., Lommerse I., Mous R., et al. VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration. Am J Physiol Cell Physiol 2003, 285:C343-C352.
134. Jones C.A., Nishiya N., London N.R., Zhu W., Sorensen L.K., Chan A.C., et al. Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nat Cell Biol 2009, 11:1325-1331.
135. Liu Z.J., Tan Y., Beecham G.W., Seo D.M., Tian R., Li Y., et al. Notch activation induces endothelial cell senescence and pro-inflammatory response: implication of Notch signaling in atherosclerosis. Atherosclerosis 2012, 225:296-303.
136. Venkatesh D., Fredette N., Rostama B., Tang Y., Vary C.P., Liaw L., et al. RhoA-mediated signaling in Notch-induced senescence-like growth arrest and endothelial barrier dysfunction. Arterioscler Thromb Vasc Biol 2011, 31:876-882.
137. Scaffidi P., Misteli T. Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing. Nat Cell Biol 2008, 10:452-459.
138. Scaffidi P., Misteli T. Lamin A-dependent nuclear defects in human aging. Science 2006, 312:1059-1063.
139. Ragnauth C.D., Warren D.T., Liu Y., McNair R., Tajsic T., Figg N., et al. Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 2010, 121:2200-2210.
140. Olive M., Harten I., Mitchell R., Beers J.K., Djabali K., Cao K., et al. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol 2010, 30:2301-2309.
141. Kovacic J.C., Moreno P., Hachinski V., Nabel E.G., Fuster V. Cellular senescence, vascular disease, and aging: part 1 of a 2-part review. Circulation 2011, 123:1650-1660.
142. Oakley R., Tharakan B. Vascular hyperpermeability and aging. Aging Dis 2014, 5:114-125.
143. Krouwer V.J., Hekking L.H., Langelaar-Makkinje M., Regan-Klapisz E., Post J.A. Endothelial cell senescence is associated with disrupted cell-cell junctions and increased monolayer permeability. Vasc Cell 2012, 4:12.
144. Coppé J.-P., Desprez P.-Y., Krtolica A., Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010, 5:99-118.
145. Campisi J., d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007, 8:729-740.
146. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965, 37:614-636.
147. Marchand A., Atassi F., Gaaya A., Leprince P., Le Feuvre C., Soubrier F., et al. The Wnt/beta-catenin pathway is activated during advanced arterial aging in humans. Aging Cell 2011, 10:220-232.
148. Morgan R.G., Ives S.J., Lesniewski L.A., Cawthon R.M., Andtbacka R.H., Noyes R.D., et al. Age-related telomere uncapping is associated with cellular senescence and inflammation independent of telomere shortening in human arteries. Am J Physiol Heart Circ Physiol 2013, 305:H251-H258.
149. Matthews C., Gorenne I., Scott S., Figg N., Kirkpatrick P., Ritchie A., et al. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res 2006, 99:156-164.
150. Cafueri G., Parodi F., Pistorio A., Bertolotto M., Ventura F., Gambini C., et al. Endothelial and smooth muscle cells from abdominal aortic aneurysm have increased oxidative stress and telomere attrition. PLoS One 2012, 7:e35312.
151. Baker D.J., Wijshake T., Tchkonia T., LeBrasseur N.K., Childs B.G., van de Sluis B., et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 2011, 479:232-236.
152. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
153. Parrinello S., Samper E., Krtolica A., Goldstein J., Melov S., Campisi J. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol 2003, 5:741-747.
154. Samper E., Nicholls D.G., Melov S. Mitochondrial oxidative stress causes chromosomal instability of mouse embryonic fibroblasts. Aging Cell 2003, 2:277-285.
155. Di Leonardo A., Linke S.P., Clarkin K., Wahl G.M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994, 8:2540-2551.
156. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005, 120:513-522.
157. Kemp C.J., Wheldon T., Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet 1994, 8:66-69.
158. Stein G.H., Drullinger L.F., Soulard A., Dulic V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol 1999, 19:2109-2117.
159. Beausejour C.M., Krtolica A., Galimi F., Narita M., Lowe S.W., Yaswen P., et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003, 22:4212-4222.
160. Jacobs J.J., de Lange T. Significant role for p16INK4a in p53-independent telomere-directed senescence. Curr Biol 2004, 14:2302-2308.
161. Brookes S., Rowe J., Ruas M., Llanos S., Clark P.A., Lomax M., et al. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J 2002, 21:2936-2945.
162. Macip S., Igarashi M., Fang L., Chen A., Pan Z.Q., Lee S.W., et al. Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence. EMBO J 2002, 21:2180-2188.
163. Narita M., Nunez S., Heard E., Narita M., Lin A.W., Hearn S.A., et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003, 113:703-716.
164. Coppe J.P., Rodier F., Patil C.K., Freund A., Desprez P.Y., Campisi J. Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype. J Biol Chem 2011, 286:36396-36403.
165. Coppe J.P., Patil C.K., Rodier F., Sun Y., Munoz D.P., Goldstein J., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008, 6:2853-2868.
166. Shelton D.N., Chang E., Whittier P.S., Choi D., Funk W.D. Microarray analysis of replicative senescence. Curr Biol 1999, 9:939-945.
167. Kyng K.J., May A., Stevnsner T., Becker K.G., Kolvra S., Bohr V.A. Gene expression responses to DNA damage are altered in human aging and in Werner Syndrome. Oncogene 2005, 24:5026-5042.
168. Yoon I.K., Kim H.K., Kim Y.K., Song I.H., Kim W., Kim S., et al. Exploration of replicative senescence-associated genes in human dermal fibroblasts by cDNA microarray technology. Exp Gerontol 2004, 39:1369-1378.
169. Zhang H., Pan K.H., Cohen S.N. Senescence-specific gene expression fingerprints reveal cell-type-dependent physical clustering of up-regulated chromosomal loci. Proc Natl Acad Sci U S A 2003, 100:3251-3256.
170. Maier J.A., Voulalas P., Roeder D., Maciag T. Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer. Science 1990, 249:1570-1574.
171. Noureddine H., Gary-Bobo G., Alifano M., Marcos E., Saker M., Vienney N., et al. Pulmonary artery smooth muscle cell senescence is a pathogenic mechanism for pulmonary hypertension in chronic lung disease. Circ Res 2011, 109:543-553.
172. Xin M.G., Zhang J., Block E.R., Patel J.M. Senescence-enhanced oxidative stress is associated with deficiency of mitochondrial cytochrome c oxidase in vascular endothelial cells. Mech Ageing Dev 2003, 124:911-919.
173. Sato I., Morita I., Kaji K., Ikeda M., Nagao M., Murota S. Reduction of nitric oxide producing activity associated with in vitro aging in cultured human umbilical vein endothelial cell. Biochem Biophys Res Commun 1993, 195:1070-1076.
174. Minamino T., Miyauchi H., Yoshida T., Ishida Y., Yoshida H., Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 2002, 105:1541-1544.
175. Chien Y., Scuoppo C., Wang X., Fang X., Balgley B., Bolden J.E., et al. Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev 2011, 25:2125-2136.
176. Salminen A., Kauppinen A., Kaarniranta K. Emerging role of NF-kappaB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell Signal 2012, 24:835-845.
177. Tilstra J.S., Robinson A.R., Wang J., Gregg S.Q., Clauson C.L., Reay D.P., et al. NF-kappaB inhibition delays DNA damage-induced senescence and aging in mice. J Clin Invest 2012, 122:2601-2612.
178. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrilova O., et al. p53 regulates mitochondrial respiration. Science 2006, 312:1650-1653.
179. Mihm M.J., Jing L., Bauer J.A. Nitrotyrosine causes selective vascular endothelial dysfunction and DNA damage. J Cardiovasc Pharmacol 2000, 36:182-187.
180. Ballinger S.W., Patterson C., Yan C.N., Doan R., Burow D.L., Young C.G., et al. Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells. Circ Res 2000, 86:960-966.
181. Mayr M., Hu Y., Hainaut H., Xu Q. Mechanical stress-induced DNA damage and rac-p38MAPK signal pathways mediate p53-dependent apoptosis in vascular smooth muscle cells. FASEB J 2002, 16:1423-1425.
182. Singh N.P., Muller C.H., Berger R.E. Effects of age on DNA double-strand breaks and apoptosis in human sperm. Fertil Steril 2003, 80:1420-1430.
183. Bua E., Johnson J., Herbst A., Delong B., McKenzie D., Salamat S., et al. Mitochondrial DNA-deletion mutations accumulate intracellularly to detrimental levels in aged human skeletal muscle fibers. Am J Hum Genet 2006, 79:469-480.
184. Herbst A., Pak J.W., McKenzie D., Bua E., Bassiouni M., Aiken J.M. Accumulation of mitochondrial DNA deletion mutations in aged muscle fibers: evidence for a causal role in muscle fiber loss. J Gerontol A Biol Sci Med Sci 2007, 62:235-245.
185. Aldred M.A., Comhair S.A., Varella-Garcia M., Asosingh K., Xu W., Noon G.P., et al. Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2010, 182:1153-1160.
186. Spandidos D.A., Ergazaki M., Arvanitis D., Kiaris H. Microsatellite instability in human atherosclerotic plaques. Biochem Biophys Res Commun 1996, 220:137-140.
187. Kiaris H., Hatzistamou J., Spandidos D.A. Instability at the H-ras minisatellite in human atherosclerotic plaques. Atherosclerosis 1996, 125:47-51.
188. Inafuku M., Toda T., Iwasaki H., Oku H. Analysis of microsatellite instability and loss of heterozygosity in human aortic atherosclerotic lesions. Rinsho Byori 2004, 52:961-965.
189. Hatzistamou J., Kiaris H., Ergazaki M., Spandidos D.A. Loss of heterozygosity and microsatellite instability in human atherosclerotic plaques. Biochem Biophys Res Commun 1996, 225:186-190.
190. Flouris G.A., Arvanitis D.A., Parissis J.T., Arvanitis D.L., Spandidos D.A. Loss of heterozygosity in DNA mismatch repair genes in human atherosclerotic plaques. Mol Cell Biol Res Commun 2000, 4:62-65.
191. Arvanitis D.A., Flouris G.A., Spandidos D.A. Genomic rearrangements on VCAM1, SELE, APEG1and AIF1 loci in atherosclerosis. J Cell Mol Med 2005, 9:153-159.
192. Durik M., Kavousi M., van der Pluijm I., Isaacs A., Cheng C., Verdonk K., et al. Nucleotide excision DNA repair is associated with age-related vascular dysfunction. Circulation 2012, 126:468-478.
193. Harley C.B., Futcher A.B., Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-460.
194. Oikawa S., Tada-Oikawa S., Kawanishi S. Site-specific DNA damage at the GGG sequence by UVA involves acceleration of telomere shortening. Biochemistry 2001, 40:4763-4768.
195. Sitte N., Saretzki G., von Zglinicki T. Accelerated telomere shortening in fibroblasts after extended periods of confluency. Free Radic Biol Med 1998, 24:885-893.
196. d'Adda di Fagagna F., Reaper P.M., Clay-Farrace L., Fiegler H., Carr P., Von Zglinicki T., et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003, 426:194-198.
197. Takai H., Smogorzewska A., de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003, 13:1549-1556.
198. Kahn B.B., Alquier T., Carling D., Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005, 1:15-25.
199. Imai S., Armstrong C.M., Kaeberlein M., Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000, 403:795-800.
200. Tissenbaum H.A., Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001, 410:227-230.
201. Rodgers J.T., Lerin C., Gerhart-Hines Z., Puigserver P. Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett 2008, 582:46-53.
202. Whittle J.R., Powell M.J., Popov V.M., Shirley L.A., Wang C., Pestell R.G. Sirtuins, nuclear hormone receptor acetylation and transcriptional regulation. Trends Endocrinol Metab 2007, 18:356-364.
203. Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature 2006, 444:868-874.
204. Cohen H.Y., Miller C., Bitterman K.J., Wall N.R., Hekking B., Kessler B., et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004, 305:390-392.
205. Dali-Youcef N., Lagouge M., Froelich S., Koehl C., Schoonjans K., Auwerx J. Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann Med 2007, 39:335-345.
206. Kao C.L., Chen L.K., Chang Y.L., Yung M.C., Hsu C.C., Chen Y.C., et al. Resveratrol protects human endothelium from H(2)O(2)-induced oxidative stress and senescence via SirT1 activation. J Atheroscler Thromb 2010, 17:970-979.
207. Donato A.J., Magerko K.A., Lawson B.R., Durrant J.R., Lesniewski L.A., Seals D.R. SIRT-1 and vascular endothelial dysfunction with ageing in mice and humans. J Physiol 2011, 589:4545-4554.
208. Lafontaine-Lacasse M., Richard D., Picard F. Effects of age and gender on Sirt 1 mRNA expressions in the hypothalamus of the mouse. Neurosci Lett 2010, 480:1-3.
209. Yeung F., Hoberg J.E., Ramsey C.S., Keller M.D., Jones D.R., Frye R.A., et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004, 23:2369-2380.
210. Mitchell S.J., Martin-Montalvo A., Mercken E.M., Palacios H.H., Ward T.M., Abulwerdi G., et al. The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep 2014, 6:836-843.
211. Mattagajasingh I., Kim C.S., Naqvi A., Yamamori T., Hoffman T.A., Jung S.B., et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 2007, 104:14855-14860.
212. Rippe C., Lesniewski L., Connell M., LaRocca T., Donato A., Seals D. Short-term calorie restriction reverses vascular endothelial dysfunction in old mice by increasing nitric oxide and reducing oxidative stress. Aging Cell 2010, 9:304-312.
213. Gano L.B., Donato A.J., Hazma M., Hearon C., Sindler A., Seals D.R. The SIRT1 activator SRT1720 reverses vascular endothelial dysfunction, excessive superoxide production and inflammation with aging in mice. Am J Physiol Heart Circ Physiol 2014, 307:H1754-H1763.
214. Csiszar A., Labinskyy N., Jimenez R., Pinto J.T., Ballabh P., Losonczy G., et al. Anti-oxidative and anti-inflammatory vasoprotective effects of caloric restriction in aging: role of circulating factors and SIRT1. Mech Ageing Dev 2009, 130:518-527.
215. Das D.K., Maulik N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interv 2006, 6:36-47.
216. Smith J.J., Kenney R.D., Gagne D.J., Frushour B.P., Ladd W., Galonek H.L., et al. Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst Biol 2009, 3:31.
217. Stivala L.A., Savio M., Carafoli F., Perucca P., Bianchi L., Maga G., et al. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem 2001, 276:22586-22594.
218. Hung L.M., Chen J.K., Huang S.S., Lee R.S., Su M.J. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res 2000, 47:549-555.
219. Leiro J., Alvarez E., Arranz J.A., Laguna R., Uriarte E., Orallo F. Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes. J Leukoc Biol 2004, 75:1156-1165.
220. Labinskyy N., Csiszar A., Veress G., Stef G., Pacher P., Oroszi G., et al. Vascular dysfunction in aging: potential effects of resveratrol, an anti-inflammatory phytoestrogen. Curr Med Chem 2006, 13:989-996.
221. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J 2003, 17:1975-1985.
222. Pearson K.J., Baur J.A., Lewis K.N., Peshkin L., Price N.L., Labinskyy N., et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008, 8:157-168.
223. Gano L.B., Seals D.R., Hazma M., Lesniewski L.A., Donato A.J. Chronic treatment with SIRT1 activator SRT1720 ameliorates age-associated vascular endothelial dysfunction in B6D2F1 mice. Circulation 2010, 122. [Abstract A10813].
224. Hattori Y., Suzuki K., Hattori S., Kasai K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006, 47:1183-1188.
225. Hardie D.G., Hawley S.A., Scott J.W. AMP-activated protein kinase-development of the energy sensor concept. J Physiol 2006, 574:7-15.
226. Fisslthaler B., Fleming I. Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ Res 2009, 105:114-127.
227. Sanz P. AMP-activated protein kinase: structure and regulation. Curr Protein Pept Sci 2008, 9:478-492.
228. Wong A.K., Howie J., Petrie J.R., Lang C.C. AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clin Sci (Lond) 2009, 116:607-620.
229. Owen M.R., Doran E., Halestrap A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000, 348(Pt 3):607-614.
230. Stephenne X., Foretz M., Taleux N., van der Zon G.C., Sokal E., Hue L., et al. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 2011, 54:3101-3110.
231. Buzzai M., Jones R.G., Amaravadi R.K., Lum J.J., DeBerardinis R.J., Zhao F., et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007, 67:6745-6752.
232. Janjetovic K., Vucicevic L., Misirkic M., Vilimanovich U., Tovilovic G., Zogovic N., et al. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur J Pharmacol 2011, 651:41-50.
233. Janjetovic K., Harhaji-Trajkovic L., Misirkic-Marjanovic M., Vucicevic L., Stevanovic D., Zogovic N., et al. In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol 2011, 668:373-382.
234. Saeedi R., Parsons H.L., Wambolt R.B., Paulson K., Sharma V., Dyck J.R., et al. Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms. Am J Physiol Heart Circ Physiol 2008, 294:H2497-H2506.
235. Li X., Han Y., Pang W., Li C., Xie X., Shyy J.Y., et al. AMP-activated protein kinase promotes the differentiation of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008, 28:1789-1795.
236. Ahluwalia A., Tarnawski A.S. Activation of the metabolic sensor-AMP activated protein kinase reverses impairment of angiogenesis in aging myocardial microvascular endothelial cells. Implications for the aging heart. J Physiol Pharmacol 2011, 62:583-587.
237. Ouchi N., Shibata R., Walsh K. AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle. Circ Res 2005, 96:838-846.
238. Nagata D., Mogi M., Walsh K. AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J Biol Chem 2003, 278:31000-31006.
239. Kanazawa I., Yamaguchi T., Yano S., Yamauchi M., Sugimoto T. Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun 2008, 375:414-419.
240. Levine Y.C., Li G.K., Michel T. Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells. Evidence for an AMPK→Rac1→Akt→endothelial nitric-oxide synthase pathway. J Biol Chem 2007, 282:20351-20364.
241. Chen Z.P., Mitchelhill K.I., Michell B.J., Stapleton D., Rodriguez-Crespo I., Witters L.A., et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 1999, 443:285-289.
242. Chen Z., Peng I.C., Sun W., Su M.I., Hsu P.H., Fu Y., et al. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res 2009, 104:496-505.
243. Majithiya J.B., Balaraman R. Metformin reduces blood pressure and restores endothelial function in aorta of streptozotocin-induced diabetic rats. Life Sci 2006, 78:2615-2624.
244. Sartoretto J.L., Melo G.A., Carvalho M.H., Nigro D., Passaglia R.T., Scavone C., et al. Metformin treatment restores the altered microvascular reactivity in neonatal streptozotocin-induced diabetic rats increasing NOS activity, but not NOS expression. Life Sci 2005, 77:2676-2689.
245. Katakam P.V., Ujhelyi M.R., Hoenig M., Miller A.W. Metformin improves vascular function in insulin-resistant rats. Hypertension 2000, 35:108-112.
246. Zu Y., Liu L., Lee M.Y., Xu C., Liang Y., Man R.Y., et al. SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells. Circ Res 2010, 106:1384-1393.
247. Lesniewski L.A., Zigler M.C., Durrant J.R., Donato A.J., Seals D.R. Sustained activation of AMPK ameliorates age-associated vascular endothelial dysfunction via a nitric oxide-independent mechanism. Mech Ageing Dev 2012, 133:368-371.
248. Pu Y., Zhang H., Wang P., Zhao Y., Li Q., Wei X., et al. Dietary curcumin ameliorates aging-related cerebrovascular dysfunction through the AMPK/uncoupling protein 2 pathway. Cell Physiol Biochem 2013, 32:1167-1177.
249. Davis B., Rahman A., Arner A. AMP-activated kinase relaxes agonist induced contractions in the mouse aorta via effects on PKC signaling and inhibits NO-induced relaxation. Eur J Pharmacol 2012, 695:88-95.
250. Sharp Z.D., Strong R. The role of mTOR signaling in controlling mammalian life span: what a fungicide teaches us about longevity. J Gerontol A Biol Sci Med Sci 2010, 65:580-589.
251. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
252. Vellai T., Takacs-Vellai K., Zhang Y., Kovacs A.L., Orosz L., Muller F. Genetics: influence of TOR kinase on lifespan in C. elegans. Nature 2003, 426(620).
253. Powers R.W., Kaeberlein M., Caldwell S.D., Kennedy B.K., Fields S. Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev 2006, 20:174-184.
254. Kapahi P., Zid B.M., Harper T., Koslover D., Sapin V., Benzer S. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol 2004, 14:885-890.
255. Jia K., Chen D., Riddle D.L. The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development 2004, 131:3897-3906.
256. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
257. Wilkinson J.E., Burmeister L., Brooks S.V., Chan C.C., Friedline S., Harrison D.E., et al. Rapamycin slows aging in mice. Aging Cell 2012, 11:675-682.
258. Selman C., Tullet J.M., Wieser D., Irvine E., Lingard S.J., Choudhury A.I., et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009, 326:140-144.
259. Reihl K., Seals D., Henson G., LaRocca T., Magerko K., Bosshardt G., et al. Dietary rapamycin selectively improves arterial function in old mice. FASEB J 2013, 27:1194.17.
260. Sethi G., Sung B., Aggarwal B.B. Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) 2008, 233:21-31.
261. Tunon M.J., Sanchez-Campos S., Gutierrez B., Culebras J.M., Gonzalez-Gallego J. Effects of FK506 and rapamycin on generation of reactive oxygen species, nitric oxide production and nuclear factor kappa B activation in rat hepatocytes. Biochem Pharmacol 2003, 66:439-445.
262. Lai J.H., Tan T.H. CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin. J Biol Chem 1994, 269:30077-30080.
263. Romano M.F., Avellino R., Petrella A., Bisogni R., Romano S., Venuta S. Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer 2004, 40:2829-2836.
264. Salminen A., Hyttinen J.M., Kaarniranta K. AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan. J Mol Med 2011, 89:667-676.
265. Yang Z., Kahn B.B., Shi H., Xue B.Z. Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem 2010, 285:19051-19059.
266. Cacicedo J.M., Yagihashi N., Keaney J.F., Ruderman N.B., Ido Y. AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem Biophys Res Commun 2004, 324:1204-1209.
267. Katerelos M., Mudge S.J., Stapleton D., Auwardt R.B., Fraser S.A., Chen C.G., et al. 5-aminoimidazole-4-carboxamide ribonucleoside and AMP-activated protein kinase inhibit signalling through NF-kappaB. Immunol Cell Biol 2010, 88:754-760.
268. Liu C., Liang B., Wang Q., Wu J., Zou M.H. Activation of AMP-activated protein kinase alpha1 alleviates endothelial cell apoptosis by increasing the expression of anti-apoptotic proteins Bcl-2 and survivin. J Biol Chem 2010, 285:15346-15355.
269. Papanicolaou K.N., Izumiya Y., Walsh K. Forkhead transcription factors and cardiovascular biology. Circ Res 2008, 102:16-31.
270. Sedding D.G. FoxO transcription factors in oxidative stress response and ageing-a new fork on the way to longevity?. Biol Chem 2008, 389:279-283.
271. Tsai K.L., Sun Y.J., Huang C.Y., Yang J.Y., Hung M.C., Hsiao C.D. Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification. Nucleic Acids Res 2007, 35:6984-6994.
272. Huang H., Regan K.M., Wang F., Wang D., Smith D.I., van Deursen J.M., et al. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A 2005, 102:1649-1654.
273. Huang H., Tindall D.J. Dynamic FoxO transcription factors. J Cell Sci 2007, 120:2479-2487.
274. Brunet A., Sweeney L.B., Sturgill J.F., Chua K.F., Greer P.L., Lin Y., et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015.
275. Paik J.H. FOXOs in the maintenance of vascular homoeostasis. Biochem Soc Trans 2006, 34:731-734.
276. Kobayashi Y., Furukawa-Hibi Y., Chen C., Horio Y., Isobe K., Ikeda K., et al. SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int J Mol Med 2005, 16:237-243.
277. Laplante M., Sabatini D.M. mTOR signaling at a glance. J Cell Sci 2009, 122:3589-3594.
278. Hong F., Larrea M.D., Doughty C., Kwiatkowski D.J., Squillace R., Slingerland J.M. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 2008, 30:701-711.
279. Greer E.L., Oskoui P.R., Banko M.R., Maniar J.M., Gygi M.P., Gygi S.P., et al. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem 2007, 282:30107-30119.
280. Ryan K.M., Phillips A.C., Vousden K.H. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 2001, 13:332-337.
281. Gorenne I., Kumar S., Gray K., Figg N., Yu H., Mercer J., et al. Vascular smooth muscle cell sirtuin 1 protects against DNA damage and inhibits atherosclerosis. Circulation 2013, 127:386-396.
282. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107:137-148.
283. Vaziri H., Dessain S.K., Ng Eaton E., Imai S.I., Frye R.A., Pandita T.K., et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159.
284. Craig A.L., Chrystal J.A., Fraser J.A., Sphyris N., Lin Y., Harrison B.J., et al. The MDM2 ubiquitination signal in the DNA-binding domain of p53 forms a docking site for calcium calmodulin kinase superfamily members. Mol Cell Biol 2007, 27:3542-3555.
285. Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005, 18:283-293.
286. Thoreen C.C., Sabatini D.M. AMPK and p53 help cells through lean times. Cell Metab 2005, 1:287-288.
287. Feng Z., Zhang H., Levine A.J., Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 2005, 102:8204-8209.